Daré Bioscience faces March 29, 2027 Nasdaq deadline

Daré has an initial compliance window through March 29, 2027, and may qualify for a second 180-day period under Nasdaq’s other listing standards.

Rhea-AI Filing Summary

Daré Bioscience, Inc. (DARE) received Nasdaq notice that its common stock’s closing bid had been below the $1.00 per share minimum for 30 consecutive business days. The notice has no immediate effect on its Nasdaq Capital Market listing. Daré has until March 29, 2027, the end of an initial 180-calendar-day period, to regain compliance. A closing bid of at least $1.00 for 10 consecutive business days would meet the price test, unless Nasdaq Staff extends that period.

If Daré does not regain compliance, it may qualify for another 180-calendar-day period by meeting the other specified listing standards and providing written notice of its intention to cure the deficiency, by effecting a reverse stock split if necessary. If Daré is ineligible for that period or Staff believes it cannot cure the deficiency, Staff would provide written notice that the stock is subject to delisting; Daré may then appeal to a Nasdaq Hearing Panel. Daré said it will monitor the closing bid and consider options, and stated there can be no assurance it will regain compliance or meet other continued-listing requirements.

0 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

How the balance works

Positive

• None.

Negative

• Moderate pointBid-price deficiency: DARE’s closing bid was below $1.00 per share for 30 consecutive business days, triggering a Nasdaq compliance period.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Minimum bid price: $1.00 per share Period below minimum bid price: 30 consecutive business days Initial compliance period: 180 calendar days +3 more

6 metrics

Minimum bid price $1.00 per share Minimum for continued listing

Period below minimum bid price 30 consecutive business days Closing bid price

Initial compliance period 180 calendar days Initial period to regain compliance

Compliance date March 29, 2027 End of initial compliance period

Consecutive-day price test 10 consecutive business days Closing bid must be at least $1.00 per share

Possible additional compliance period 180 calendar days Daré may qualify if it meets specified listing standards

Key Terms

Minimum Bid Price Requirement, market value of publicly held shares, Nasdaq Hearing Panel

3 terms

Minimum Bid Price Requirement regulatory

"the “Minimum Bid Price Requirement”"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

market value of publicly held shares regulatory

"continued listing requirement for the market value of publicly held shares"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

Nasdaq Hearing Panel regulatory

"appeal the Staff’s delisting determination to a Nasdaq Hearing Panel"

A Nasdaq hearing panel is a group of independent reviewers who decide whether a publicly listed company has broken the exchange’s rules and what penalties, if any, should apply. Think of it like a neighborhood committee that reviews complaints and can impose fines, require fixes, or remove a member; for investors, the panel’s rulings can affect whether a stock keeps trading, faces suspension, or suffers reputational and price impact.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is DARE’s Nasdaq bid-price compliance deadline?

Daré has until March 29, 2027, to regain compliance with Nasdaq’s $1.00-per-share minimum bid-price requirement. This is the end of its initial 180-calendar-day compliance period.

Can DARE appeal a Nasdaq delisting decision?

If Nasdaq Staff determines that the stock is subject to delisting, Daré may appeal the Staff’s delisting determination to a Nasdaq Hearing Panel. Staff would provide written notice if Daré is ineligible for an additional compliance period or appears unable to cure the deficiency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:02 PM Accepted by SEC EDGAR 10/02/2026 - 04:01 PM Learn about SEC filing dates

0001401914FALSE00014019142026-04-132026-04-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 28, 2026

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36395

20-4139823

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock			DARE			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 28, 2026, Daré Bioscience, Inc. (“Daré”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying Daré that, for the last 30 consecutive business days, the closing bid price for Daré’s common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The letter has no immediate effect on the listing of Daré’s common stock on the Nasdaq Capital Market.

In accordance with Nasdaq listing rules, Daré has been provided an initial period of 180 calendar days, or until March 29, 2027 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement. If, at any time during this 180-day period, the closing bid price of Daré’s common stock is at least $1.00 for a minimum of 10 consecutive business days, unless the Staff exercises its discretion to extend such 10-day period, the Staff will provide Daré written confirmation of compliance with the Minimum Bid Price Requirement and the matter will be closed. If Daré does not regain compliance by the Compliance Date, Daré may be eligible for an additional 180 calendar day compliance period. To qualify for such additional compliance period, Daré would have to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the Minimum Bid Price Requirement, and Daré would need to provide written notice of its intention to cure the deficiency during the additional compliance period, by effecting a reverse stock split, if necessary. If Daré is not eligible for the additional compliance period or if it appears to the Staff that Daré will not be able to cure the deficiency, the Staff will provide written notice to Daré that its common stock will be subject to delisting. At that time, Daré may appeal the Staff’s delisting determination to a Nasdaq Hearing Panel.

Daré will monitor the closing bid price of its common stock and will consider options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that Daré will regain compliance with the Minimum Bid Price Requirement or maintain compliance with any other Nasdaq continued listing requirement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DARÉ BIOSCIENCE, INC.

Dated: October 2, 2026

By:

/s/ Sabrina Martucci Johnson

Name:

Sabrina Martucci Johnson

Title:

President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.2 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB